VivoSeq
Hematology

Eosinophilia

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Eosinophilia is an early-stage landscape with 0 programs across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Recruiting2 · 50%
Completed1 · 25%
Terminated1 · 25%

Clinical Trials

Trial Activity

Montelukast in the Treatment of Duodenal Eosinophilia
Completed·—·N/A·NCT00148603·24 enrolled
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
Terminated·Novartis logoNovartis·Phase 2·NCT03810183·9 enrolled
Specific Versus Empirical Anthelminthic Treatment in Eosinophilia
Recruiting·PPrince of Songkla University·N/A·NCT06265870·700 enrolled
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00091871·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)